{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T13:40:49Z","timestamp":1772804449910,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2003,6,1]],"date-time":"2003-06-01T00:00:00Z","timestamp":1054425600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2003,6,1]],"date-time":"2003-06-01T00:00:00Z","timestamp":1054425600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2003,6]]},"DOI":"10.1007\/bf02986621","type":"journal-article","created":{"date-parts":[[2008,11,12]],"date-time":"2008-11-12T22:35:44Z","timestamp":1226529344000},"page":"512-517","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Phase II Study of Cladribine (2-Chlorodeoxyadenosine) in Relapsed or Refractory Adult T-Cell Leukemia-Lymphoma"],"prefix":"10.1007","volume":"77","author":[{"given":"Kensei","family":"Tobinai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naokuni","family":"Uike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshio","family":"Saburi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaaki","family":"Chou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Etoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumio","family":"Kawano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masao","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirokuni","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Torahiko","family":"Makino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinobu","family":"Asano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuo","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2003,6,1]]},"reference":[{"key":"BF02986621_CR1","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1182\/blood.V50.3.481.481","volume":"50","author":"T Uchiyama","year":"1977","unstructured":"Uchiyama T, Yodoi J, Sagawa K, et al. Adult T-cell leukemia: clini- cal and hematologic features of 16 cases.Blood. 1977;50:481\u2013492.","journal-title":"Blood"},{"key":"BF02986621_CR2","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1073\/pnas.79.6.2031","volume":"79","author":"M Yoshida","year":"1982","unstructured":"Yoshida M, Miyoshi I, Hinuma Y. Isolation and characterization of retrovirus from cell lines of human adult T cell leukemia and its implication in the disease.Proc NatlAcad Sci USA. 1982;79:2031\u20132035.","journal-title":"Proc NatlAcad Sci USA"},{"key":"BF02986621_CR3","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/j.1365-2141.1991.tb08051.x","volume":"79","author":"M. Shimoyama","year":"1991","unstructured":"Shimoyama M. Diagnostic criteria and classification of clinical sub- types of adult T-cell leukaemia-lymphoma: a report from the Lym- phoma Study Group (1984-87).Br J Haematol. 1991;79:428\u2013437.","journal-title":"Br J Haematol"},{"key":"BF02986621_CR4","first-page":"2748","volume-title":"Clinical Oncology.","author":"K. Tobinai","year":"2000","unstructured":"Tobinai K. Adult T-cell leukemia-lymphoma. In: Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE, eds.Clinical Oncology. 2nd ed. New York, NY: Churchill Livingstone; 2000:2748\u20132768.","edition":"2nd ed."},{"key":"BF02986621_CR5","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1200\/JCO.1988.6.1.128","volume":"6","author":"M Shimoyama","year":"1988","unstructured":"Shimoyama M, Ota K, Kikuchi M, et al. Chemotherapeutic results and prognostic factors of patients with advanced non-Hodgkin\u2019s lymphoma treated with VEPA or VEPA-M.J Clin Oncol. 1988;6:128\u2013141.","journal-title":"J Clin Oncol"},{"key":"BF02986621_CR6","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1200\/JCO.1988.6.7.1088","volume":"6","author":"M Shimoyama","year":"1988","unstructured":"Shimoyama M, Ota K, Kikuchi M, et al. Major prognostic factors of adult patients with advanced T-cell Iymphoma\/leukemia.J Clin Oncol. 1988;6:1088\u20131097.","journal-title":"J Clin Oncol"},{"key":"BF02986621_CR7","first-page":"378","volume":"13","author":"K Tobinai","year":"1994","unstructured":"Tobinai K, Shimoyama M, Minato K, et al. Japan Clinical Oncology Group phase II trial of second-generation \u201cLSG4 protocol\u201d in aggressive T- and B-lymphoma: a new predictive model for T- and B-lymphoma [abstract].Proc Am Soc Clin Oncol. 1994;13:378.","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF02986621_CR8","first-page":"164","volume":"22","author":"K Tobinai","year":"1992","unstructured":"Tobinai K, Shimoyama M, Inoue S, et al. Phase I study of YK-176 (2\u2019-deoxycoformycin) in patients with adult T-cell leukemia- lymphoma.Jpn J Clin Oncol. 1992;22:164\u2013171.","journal-title":"Jpn J Clin Oncol"},{"key":"BF02986621_CR9","first-page":"221","volume-title":"Adult T-cell Leukaemia.","author":"M Shimoyama","year":"1994","unstructured":"ShimoyamaM. Chemotherapy of ATL. In: TakatsukiK, ed.Adult T-cell Leukaemia. Oxford, UK: Oxford University Press; 1994:221."},{"key":"BF02986621_CR10","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1007\/BF02983215","volume":"77","author":"K Tsukasaki","year":"2003","unstructured":"Tsukasaki K, Tobinai K, Shimoyama M, et al. Deoxycoformycin- containing combination chemotherapy for adult T-cell leukemia- lymphoma: Japan Clinical Oncology Group Study (JCOG9109).Int J Hematol. 2003;77:164\u2013170.","journal-title":"Int J Hematol"},{"key":"BF02986621_CR11","doi-asserted-by":"publisher","first-page":"5677","DOI":"10.1073\/pnas.74.12.5677","volume":"77","author":"DA Carson","year":"1977","unstructured":"Carson DA, Kaye J, Seegmiller JE. Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphory- lase deficiency: possible role of nucleoside kinase(s).Proc Natl AcadSci USA. 1977;77:5677\u20135681.","journal-title":"Proc Natl AcadSci USA"},{"key":"BF02986621_CR12","doi-asserted-by":"publisher","first-page":"6865","DOI":"10.1073\/pnas.77.11.6865","volume":"77","author":"DA Carson","year":"1980","unstructured":"Carson DA,Wasson DB, Kaye J, et al. Deoxycytidine kinase-medi- ated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo.Proc Natl Acad Sci USA. 1980;77:6865\u20136869.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BF02986621_CR13","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/0140-6736(92)92826-2","volume":"340","author":"E. Beutler","year":"1992","unstructured":"Beutler E. Cladribine (2-chlorodeoxyadenosine).Lancet. 1992;340:952\u2013956.","journal-title":"Lancet"},{"key":"BF02986621_CR14","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJM199004193221605","volume":"322","author":"LD Piro","year":"1990","unstructured":"Piro LD, Carrera CJ, Carson DA, Beutler E. Lasting remissions in hairy-cell leukemia induced by single infusion of 2-chlorodeoxyadenosine.N Engl J Med. 1990;322:1117\u20131121.","journal-title":"N Engl J Med"},{"key":"BF02986621_CR15","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1182\/blood.V80.9.2203.2203","volume":"80","author":"MS Tallman","year":"1992","unstructured":"Tallman MS, Hakimian D, Variakojis D, et al. A single cycle of 2-chlorodeoxyadenosine results in complete remission in the majority of patients with hairy cell leukemia.Blood. 1992;80:2203\u20132209.","journal-title":"Blood"},{"key":"BF02986621_CR16","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1200\/JCO.1993.11.4.679","volume":"11","author":"G Juliusson","year":"1993","unstructured":"Juliusson G, Liliemark J. High complete remission rate of 2-chloro-2\u2019-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: response predicted by rapid decrease of blood lymphocyte count.J Clin Oncol. 1993;11:679\u2013689.","journal-title":"J Clin Oncol"},{"key":"BF02986621_CR17","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1200\/JCO.1995.13.3.570","volume":"13","author":"A Saven","year":"1995","unstructured":"Saven A, Lemon RH, Kosty M, Beutler E, Piro LD. 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia.J Clin Oncol. 1995;13:570\u2013574.","journal-title":"J Clin Oncol"},{"key":"BF02986621_CR18","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1200\/JCO.1992.10.11.1821","volume":"10","author":"K Barton","year":"1992","unstructured":"Barton K, Larson RA, O\u2019Brien S, Ratain MJ. Rapid response of B-cell prolymphocytic leukemia to 2-chlorodeoxyadenosine [let- ter].J Clin Oncol. 1992;10:1821.","journal-title":"J Clin Oncol"},{"key":"BF02986621_CR19","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1200\/JCO.1992.10.3.371","volume":"10","author":"AC Kay","year":"1992","unstructured":"Kay AC, Saven A, Carrera CJ, Carson DA, Beutler E, Piro LD. 2-Chlorodeoxyadenosine treatment of low-grade lymphomas.J Clin Oncol. 1992;10:371\u2013377.","journal-title":"J Clin Oncol"},{"key":"BF02986621_CR20","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1200\/JCO.1994.12.4.788","volume":"12","author":"M Hoffman","year":"1994","unstructured":"Hoffman M,Tallman MS, Hakimian D, et al. 2-Chlorodeoxyadenosine is an active salvage therapy in advanced non-Hodgkin\u2019s lymphoma.J Clin Oncol. 1994;12:788\u2013792.","journal-title":"J Clin Oncol"},{"key":"BF02986621_CR21","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1182\/blood.V86.5.1710.bloodjournal8651710","volume":"86","author":"A Saven","year":"1995","unstructured":"Saven A, Emanuele S, Kosty M, Koziol J, Ellison D, Piro L. 2-Chlorodeoxyadenosine activity in patients with untreated, indo- lent non-Hodgkin\u2019s lymphoma.Blood. 1995;86:1710\u20131716.","journal-title":"Blood"},{"key":"BF02986621_CR22","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1172\/JCI111710","volume":"75","author":"S Seto","year":"1985","unstructured":"Seto S, Carrera CJ, Kubota M, Wasson DB, Carson DA. Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondi- viding human lymphocytes.J Clin Invest. 1985;75:377\u2013383.","journal-title":"J Clin Invest"},{"key":"BF02986621_CR23","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1182\/blood.V80.3.587.587","volume":"80","author":"A Saven","year":"1992","unstructured":"Saven A, Carrera CJ, Carson DA, Beutler E, Piro LD. 2-Chlorodeoxyadenosine: an active agent in the treatment of cuta- neous T-cell lymphoma.Blood. 1992;80:587\u2013592.","journal-title":"Blood"},{"key":"BF02986621_CR24","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1182\/blood.V84.3.733.733","volume":"84","author":"S O\u2019Brien","year":"1994","unstructured":"O\u2019Brien S, Kurzrock R, Duvic M, et al. 2-Chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders.Blood. 1994;84:733\u2013738.","journal-title":"Blood"},{"key":"BF02986621_CR25","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1182\/blood.V87.3.906.bloodjournal873906","volume":"87","author":"TM Kuzel","year":"1996","unstructured":"Kuzel TM, Hurria A, Samuelson E, et al. Phase II trial of 2-chlorodeoxyadenosine for the treatment of cutaneous T-cell lym- phoma.Blood. 1996;87:906\u2013911.","journal-title":"Blood"},{"key":"BF02986621_CR26","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1093\/jjco\/27.3.146","volume":"27","author":"K Tobinai","year":"1997","unstructured":"Tobinai K, Ogura M, Hotta T, et al. Phase I study of cladribine (2-chlorodeoxyadenosine) in lymphoid malignancies.Jpn J Clin Oncol. 1997;27:146\u2013153.","journal-title":"Jpn J Clin Oncol"},{"key":"BF02986621_CR27","doi-asserted-by":"publisher","first-page":"411","DOI":"10.2169\/internalmedicine.37.411","volume":"37","author":"N Uike","year":"1998","unstructured":"Uike N, Choi I, Tokoro A, et al. Adult T-cell leukemia-lymphoma successfully treated with 2-chlorodeoxyadenosine.Intern Med. 1998;37:411\u2013413.","journal-title":"Intern Med"},{"key":"BF02986621_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R. Simon","year":"1989","unstructured":"Simon R. Optimal two-stage designs for phase II clinical trials.Control Clin Trials. 1989;10:1\u201310.","journal-title":"Control Clin Trials"},{"key":"BF02986621_CR29","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group.Am J Clin Oncol. 1982;5:649\u2013655.","journal-title":"Am J Clin Oncol"},{"key":"BF02986621_CR30","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/oxfordjournals.jjco.a039642","volume":"23","author":"K Tobinai","year":"1993","unstructured":"Tobinai K, Kohno A, Shimada Y, et al. Toxicity grading criteria of the Japan Clinical Oncology Group (JCOG).Jpn J Clin Oncol. 1993;23:250\u2013257.","journal-title":"Jpn J Clin Oncol"},{"key":"BF02986621_CR31","volume-title":"WHO Handbook for Reporting Results of Cancer Treatment.","author":"World Health Organization","year":"1979","unstructured":"World Health Organization.WHO Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland: World Health Organization; 1979. Publication No. 48."},{"key":"BF02986621_CR32","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1046\/j.1365-2141.2001.02737.x","volume":"113","author":"Y Yamada","year":"2001","unstructured":"Yamada Y, Tomonaga M, Fukuda H, et al. A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia- lymphoma: Japan Clinical Oncology Group Study 9303.Br J Haematol. 2001;113:375\u2013382.","journal-title":"Br J Haematol"},{"key":"BF02986621_CR33","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1097\/00042560-199606010-00012","volume":"12","author":"H Taguchi","year":"1996","unstructured":"Taguchi H, Kinoshita K, Takatsuki K, et al. An intensive chemo- therapy of adult T-cell leukemia\/lymphoma: CHOP followed by etoposide, vindesine, ranimustine, and mitoxantrone with granulo- cyte colony-stimulating factor support.J Acquir Immune Defic Syndr Hum Retrovirol. 1996;12:182\u2013186.","journal-title":"J Acquir Immune Defic Syndr Hum Retrovirol"},{"key":"BF02986621_CR34","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1182\/blood.V81.10.2810.2810","volume":"81","author":"JA Sparano","year":"1993","unstructured":"Sparano JA, Wiernik PH, Strack M, et al. Infusional cyclophos- phamide, doxorubicin, and etoposide in human immunodefi- ciency virus- and human T-cell leukemia virus type I-related non- Hodgkin\u2019s lymphoma: a highly active regimen.Blood. 1993;81:2810\u20132815.","journal-title":"Blood"},{"key":"BF02986621_CR35","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1182\/blood.V82.6.1701.1701","volume":"82","author":"TA Waldmann","year":"1993","unstructured":"Waldmann TA, White JD, Goldman CK, et al. The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotropic virus I-induced adult T-cell leukemia.Blood. 1993;82:1701\u20131712.","journal-title":"Blood"},{"key":"BF02986621_CR36","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1182\/blood.V86.11.4063.bloodjournal86114063","volume":"86","author":"TA Waldmann","year":"1995","unstructured":"Waldmann TA, White JD, Carrasquillo JA, et al. Radioimmunotherapy of interleukin-2R\u03b1-expressing adult T-cell leukemia with yttrium-90-labeled anti-Tac.Blood. 1995;86:4063\u20134075.","journal-title":"Blood"},{"key":"BF02986621_CR37","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1182\/blood-2002-01-0107","volume":"100","author":"M Zhang","year":"2002","unstructured":"Zhang M, Yao Z, Garmestani K, et al. Pretargeting radioim- munotherapy of a murine model of adult T-cell leukemia with the \u03b1-emitting radionuclide, bismuth 213.Blood. 2002;100:208\u2013216.","journal-title":"Blood"},{"key":"BF02986621_CR38","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1046\/j.1365-2141.1998.01068.x","volume":"103","author":"K Ishitsuka","year":"1998","unstructured":"Ishitsuka K, Hanada S, Suzuki S, et al. Arsenic trioxide inhibits growth of human T-cell leukaemia virus type I infected T-cell lines more effectively than retinoic acids.Br J Haematol. 1998;103:721\u2013728.","journal-title":"Br J Haematol"},{"key":"BF02986621_CR39","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1182\/blood.V93.1.278","volume":"93","author":"A Bazarbachi","year":"1999","unstructured":"Bazarbachi A, El-Sabban ME, Nasr R, et al. Arsenic trioxide and interferon-alpha synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells.Blood. 1999;93:278\u2013283.","journal-title":"Blood"},{"key":"BF02986621_CR40","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/sj.bmt.1702731","volume":"27","author":"A Utsunomiya","year":"2001","unstructured":"Utsunomiya A, Miyazaki Y, Takatsuka Y, et al. Improved outcome of adult T cell leukemia\/lymphoma with allogeneic hematopoietic stem cell transplantation.Bone Marrow Transplant. 2001;27:15\u201320.","journal-title":"Bone Marrow Transplant"},{"key":"BF02986621_CR41","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/BF02982725","volume":"76","author":"Y Abe","year":"2002","unstructured":"Abe Y, Yashiki S, Choi I, et al. Eradication of virus-infected T-cells in a case of adult T-cell leukemia\/lymphoma by nonmyeloablative peripheral blood stem cell transplantation with conditioning con- sisting of low-dose total body irradiation and pentostatin.Int J Hematol. 2002;76:91\u201393.","journal-title":"Int J Hematol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF02986621\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02986621.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02986621","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02986621.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,10]],"date-time":"2020-05-10T05:49:41Z","timestamp":1589089781000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF02986621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,6]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2003,6]]}},"alternative-id":["BF02986621"],"URL":"https:\/\/doi.org\/10.1007\/bf02986621","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,6]]}}}